Medigrand Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 5.00 Cr
as on 19-12-2024
- Paid Up Capital ₹ 5.00 Cr
as on 19-12-2024
- Company Age 13 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 4.00 Cr
as on 19-12-2024
- Satisfied Charges ₹ 3.47 Cr
as on 19-12-2024
- Revenue 42.63%
(FY 2022)
- Profit 29.22%
(FY 2022)
- Ebitda 169.46%
(FY 2022)
- Net Worth -14.07%
(FY 2022)
- Total Assets -4.07%
(FY 2022)
About Medigrand Pharmaceuticals
The Corporate was formerly known as Baksen Pharmaceuticals Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 Cr and a paid-up capital of Rs 5.00 Cr.
The company currently has active open charges totaling ₹4.00 Cr. The company has closed loans amounting to ₹3.47 Cr, as per Ministry of Corporate Affairs (MCA) records.
Ayyakannu Sivakumar, Muthamilan Vivekanandhan, and Narasimman Suresh serve as directors at the Company.
- CIN/LLPIN
U24297TN2011PTC081348
- Company No.
081348
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 Jul 2011
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Dharmapuri, Tamil Nadu, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Medigrand Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Narasimman Suresh  | Managing Director | 06-Jul-2022 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Ayyakannu Sivakumar | Director | 30-Nov-2021 | Current |
| Muthamilan Vivekanandhan | Director | 30-Nov-2021 | Current |
Financial Performance of Medigrand Pharmaceuticals.
Medigrand Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 42.63% increase. The company also saw a substantial improvement in profitability, with a 29.22% increase in profit. The company's net worth observed a substantial decline by a decrease of 14.07%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Medigrand Pharmaceuticals?
In 2023, Medigrand Pharmaceuticals had a promoter holding of 53.95% and a public holding of 46.05%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Thagadur Uzhavar Producer Company LimitedActive 9 years 4 months
Ayyakannu Sivakumar is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of India Creation Date: 03 Jul 2024 | ₹4.00 Cr | Open |
Indian Bank Creation Date: 31 Jan 2024 | ₹2.20 M | Satisfied |
Others Creation Date: 27 Dec 2016 | ₹3.25 Cr | Satisfied |
How Many Employees Work at Medigrand Pharmaceuticals?
Medigrand Pharmaceuticals has a workforce of 0 employees as of Mar 30, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Medigrand Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Medigrand Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
